共 50 条
- [41] A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignanciesBreast Cancer Research and Treatment, 2016, 155 : 521 - 530Amy Jo ChienAlyson CockerillCraig FancourtEmmett SchmidtMark M. MoasserHope S. RugoMichelle E. MeliskoAndrew H. KoR. Katie KelleyW. Michael KornLaura J. EssermanLaura van‘t VeerChristina YauDenise M. WolfPamela N. Munster
- [42] Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine plus /- nab-paclitaxel.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Bashir, BabarSharma, ManishJuric, DejanPapadopoulos, Kyriakos P.Hamilton, Erika P.Richardson, Debra L.Shapiro, GeoffreySahai, VaibhavMettu, Niharika B.Wainberg, Zev A.Alese, Olatunji B.Dragovich, TomislavHodgson, GraemeHenry, SusanHall, TerencePaul, SofiaRoth, David A.Kelly, MichaelMalak, Tanya AbdulKlimek, Virginia
- [43] A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Harb, W. A.Sessa, C.Hirte, H. W.Kaye, S. B.Simantov, R.Banerjee, S. N.Christinat, A.Sternberg, D. W.Singh, M.Light, R.Poondru, S.
- [44] Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)CANCER RESEARCH, 2024, 84 (07)Migden, Michael R.Chai-Ho, WanxingDaniels, Gregory A.Medina, TheresaWise-Draper, Trisha M.Kheterpal, MeenalTang, Jennifer C.Ibrahim, Sherrif F.Bolotin, DianaVerschraegen, ClaireZeitouni, Nathalie C.Tsai, Katy K.Donthireddy, LaxminarasimhaBommareddy, Praveen K.Hou, Jeannie W.Hong, WalterDavar, Diwakar
- [45] An open label, multicenter, phase 1 b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Tolcher, Anthony W.Munster, Pamela N.Rosen, Lee S.Murphy, CurranArgueta, ChristianKuida, KeisukeRuiz-Soto, RodrigoJanku, Filip
- [46] Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)EUROPEAN JOURNAL OF CANCER, 2014, 50 : 152 - 152Kapoun, A.O'Reilly, E.Cohn, A.Bendell, J. C.Smith, L.Strickler, J. H.Gluck, W.Liu, Y. W.Wallace, B.Tam, R.Cancilla, B.Brunner, A.Hill, D.Zhou, L.Dupont, J.Zhang, C.Wang, M.
- [47] A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132).CANCER RESEARCH, 2022, 82 (12)Spigel, DavidSpira, AlexanderZamarin, DmitriyMcDermott, David F.Luke, JasonHeymach, John V.Previs, RebeccaSullivan, RyanGandhi, LeenaAzrilevich, AlexRizvi, NaiyerOft, MartinBusby, NatalieIzar, Benjamin
- [48] Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b studyCTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (06):Baranda, Joaquina C.Robbrecht, DebbieSullivan, RyanDoger, BernardSantoro, ArmandoBarve, MinalGrob, Jean-JacquesBechter, OliverVieito, Mariade Miguel, Maria JoseSchadendorf, DirkJohnson, MelissaPouzin, ClemenceCantalloube, CathyWang, RuiLee, JooyunChen, XiaofeiDemers, BrigitteAmrate, AmeleAbbadessa, GiovanniHodi, F. Stephen
- [49] A phase 1b study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumorsMOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)Davis, S. LindseyLam, Elaine T.Corr, Bradley R.O'Bryant, Cindy L.Glode, AshleyAdler, NicholePitts, Todd M.Tentler, John J.Capasso, AnnaDailey, KyrieSerkova, Natalie J.Weekes, Colin D.Gustafson, Daniel L.Lieu, Christopher H.Messersmith, Wells A.Leong, StephenEckhardt, S. GailDiamond, Jennifer R.
- [50] Initial results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody ®) in combination with pembrolizumab (an anti-PD-1 antibody) in patients with advanced/metastatic solid tumorsCANCER RESEARCH, 2023, 83 (08)Li, DanengSharma, SunilShe, KristineLi, WendaLi, AiZheng, SongmaoLiu, GuizhongNdukwo, OgonHu-Lowe, DanaChisamore, MichaelLuo, PeterZha, JipingPatel, Manish R.